Another great move and step forward towards the commercialisation of this product.
As Bedger says the Aussie market and fund managers are tone deaf to the biotech sector.
The needle will move with increasing sales and US FDA approvals - we will get there and the rewards will be significant.
Ann: Leading US-based nerve surgeons appointed to advisory board, page-12
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $82.68M | |||
| Open | High | Low | Value | Volume |
| 39.5¢ | 40.0¢ | 39.5¢ | $49.19K | 123.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 20547 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 113528 | 5 |
View Market Depth
| Last trade - 11.18am 16/07/2024 (20 minute delay) ? |
| OCC (ASX) Chart |